J. Goldman & CO LP Rigel Pharmaceuticals Inc Call Options Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding RIGL
# of Institutions
8Shares Held
334KCall Options Held
0Put Options Held
0-
Telemetry Investments, L.L.C. New York, NY323KShares$5.53 Million0.76% of portfolio
-
Bergan Kdv Wealth Management, LLC10KShares$171,5000.0% of portfolio
-
Ifp Advisors, Inc1KShares$17,1500.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA667Shares$11,4390.0% of portfolio
-
Ever Source Wealth Advisors, LLC63Shares$1,0800.0% of portfolio
About RIGEL PHARMACEUTICALS INC
- Ticker RIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 172,836,000
- Market Cap $2.96B
- Description
- Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...